Eli Lilly to acquire POINT Biopharma for radioligand therapies

Eli Lilly and Company announced a definitive agreement to acquire POINT Biopharma, a radiopharmaceutical company with a pipeline of radioligand therapies for cancer. The acquisition includes POINT's manufacturing campus in Indianapolis and R&D center in Toronto.

“We are excited by the potential of this emerging modality and see the acquisition of POINT as the beginning of our investment in developing multiple meaningful radioligand medicines for hard-to-treat cancers.”investor.lilly.com

• 1 source
• investor.lilly.comLilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies | Eli Lilly and CompanyEli Lilly, CompanyOct 3, 2023

Summarized from public sources; check the original articles before acting on it.